Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endogenex PEF Therapy + Semaglutide in Type 2 Diabetes
NCT05984238Completed
- Sponsor
- University of Amsterdam
- Start
- Aug 2023
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Amsterdam. Primary endpoints: Incidence rate of procedure-related SAEs, UADEs, SADEs, AESIs at 24 weeks and Percentage of patients off insulin at 24 weeks. Started Aug 2023; status: completed.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05984238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984238.